Beatson West

Oct 23, 2024 | bmccancer.biomedcentral.com | Beatson West

Angiogenesis has been validated as a target in multiple clinical trials that have compared conventional therapy to the same regimen supplemented by anti-angiogenic Vascular Endothelial Growth Factor inhibitors (VEGFi) [1,2,3]. In many tumour types, these studies have shown that VEGFi improve Progression Free Survival (PFS) and, in some cases, Overall Survival (OS).

May 16, 2024 | bmccancer.biomedcentral.com | Beatson West |NHS Greater Glasgow

A total of 122 patients attended the WoS-BTC clinic between September 2019 and September 2021, with a diagnosis of BTC made between November 2013 and August 2021 (Fig. 1). Median follow up time from date of diagnosis was 12.98 months. Sixty-four (52%) and 58 patients (48%) were female and male, respectively. Median age at diagnosis was 66 years (range 28–84), with the following distribution per age group: <40 (3 [2%]); 40–59 (32 [26%]); 60–79 (82 [67%]); ≥80 (5 [4%]).

Oct 6, 2023 | jmedicalcasereports.biomedcentral.com | Beatson West

Case presentationA 37-year old Caucasian man presented to the emergency department with a 6-week history of a painless, left inguinal lump. There were no systemic symptoms. He had no significant past medical history, was a non-smoker, did not drink alcohol, and was not on any regular medication. He worked as a self-employed joiner. Family history included leukemia in a paternal uncle, pharyngeal cancer in a paternal aunt, and Ewing’s sarcoma in a maternal aunt.

Aug 3, 2023 | redjournal.org | Beatson West

IMPORT LOW is a randomized, multi-center phase III trial testing partial breast radiotherapy (RT) using intensity modulated RT in women with early-stage breast cancer at lower than average risk of ipsilateral breast tumor relapse (IBTR). Five-year results concluded non-inferiority for reduced-dose & partial-breast RT with similar normal tissue effects (reduced for breast appearance & hardness as reported by patients; Lancet, 2017). Here we report outcomes after 10 years.

May 8, 2023 | ashpublications.org | Beatson West |Pier Luigi

Marginal zone lymphoma (MZL) is an indolent non-Hodgkin lymphoma, which accounts for ∼7% of mature B-cell non-Hodgkin lymphoma and has 3 main subtypes: (1) extranodal MZL of mucosa-associated lymphoid tissue, which is the most common, occurring in ∼60% of cases; (2) nodal MZL, occurring in ∼30% of cases; and (3) splenic MZL, occurring in ∼10% of cases.1,2 Conventional treatments for relapsed/refractory (R/R) MZL include immunotherapy (eg, rituximab), chemoimmunotherapy (eg,...